Study of ADXS-504 Immunotherapy for Recurrent Prostate Cancer
- First Posted Date
- 2021-10-14
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Mark Stein
- Target Recruit Count
- 8
- Registration Number
- NCT05077098
- Locations
- 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition
Phase 2
Recruiting
- Conditions
- Kidney CancerRenal Cell Carcinoma
- Interventions
- First Posted Date
- 2020-03-26
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Mark Stein
- Target Recruit Count
- 48
- Registration Number
- NCT04322955
- Locations
- 🇺🇸
The Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸Columbia University Irving Medical Center, New York, New York, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer
Phase 2
Active, not recruiting
- Conditions
- Prostate Cancer Metastatic
- Interventions
- First Posted Date
- 2019-05-15
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Mark Stein
- Target Recruit Count
- 26
- Registration Number
- NCT03951831
- Locations
- 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)
Phase 1
Active, not recruiting
- Conditions
- Prostate CancerAdenocarcinoma of the Prostate
- Interventions
- First Posted Date
- 2018-09-28
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Mark Stein
- Target Recruit Count
- 59
- Registration Number
- NCT03689699
- Locations
- 🇺🇸
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
🇺🇸Sidney Kimmel Cancer Center- Thomas Jefferson University, Philadelphia, Pennsylvania, United States
🇺🇸Columbia University Irving Medical Center, New York, New York, United States
© Copyright 2025. All Rights Reserved by MedPath